Clopidogrel in systemic sclerosis

Not Applicable

Completed

• Conditions: Systemic Sclerosis/Rheumatology; Skin and Connective Tissue Diseases; Systemic sclerosis

• Registration Number: ISRCTN63206606
• Lead Sponsor: niversity of Patras Research Committee (ELKE)

Brief Summary

2016 results in: https://www.ncbi.nlm.nih.gov/pubmed/27188755

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-12-02
• Study Completion: 2014-12-05
• Last Update Posted: 19 March 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Scleroderma diagnosis based on 2012 ACR/EULAR classification criteria
2. Age over 18

Exclusion Criteria

1. History of endocranial bleeding
2. History of gastrointestinal ulcer
3. Renal failure,EGFR less than 30ml/min based on MDRD formula

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patients will be assessed after 1 year of treatment.<br>1. Improvement of FVC and/or DLco more than 10% <br>2. Improvement of MRSS skin score more than 20%

Secondary Outcome Measures

Name	Time	Method
1. Improvement of laboratory endothelial markers(s-VCAM & s-ICAM)<br>2. Reduction in serotonin levels in platelet poor plasma